Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLUNEXT: Diltiazem for Severe Influenza A
NCT03212716Phase 2Terminated
- Sponsor
- CHU de Lille
- Start
- Dec 2017
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Influenza A (IAV) comparing Diltiazem Arm with Placebo Arm (2 arms). Primary endpoint: Percentage of alive patients without detection of influenza A virus by RT-PCR in nasopharyngeal swabs at 7 days. Started Dec 2017; status: terminated.
02
Drugs
diltiazem
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT03212716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03212716.